Table 3.

Stratified Cox proportional hazards model for survival with clinical endpoints and immune monitoring ratios

Covariate*	Hazard Ratio	95% C.I. for Hazard Ratio	p-value
Age (1 unit increase in years)	1.03	(0.99, 1.08)	0.187
Gender (Female vs Male)	1.77	(0.51, 6.10)	0.368
KPS	0.92	(0.86, 0.98)	0.010
Overall Tumor Path Effects			0.023
Recurrent Grade IV vs. newly dx Grade IV	4.42	(1.46, 13.38)	0.009
Recurrent Grade IV vs. Grade III	6.86	(0.62, 75.91)	0.116
Grade IV vs. Grade III	1.55	(0.15, 15.56)	0.709
Treg cell fold change**	7.19	(1.87, 27.73)	0.004
Activated NK cell fold change**	1.99	(0.92, 4.31)	0.081

^*Each model includes a single covariate. Stratification is on trials.

^**Refers to frequency of cells (%) at post-DC vaccination/pre-DC vaccination